Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Kim C. Ohaegbulam, Amer Assal, Eszter Lazar-Molnar, Yu Yao, Xingxing Zang

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

The programmed death 1 (PD-1) receptor and its ligands programmed death ligand 1 (PD-L1) and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition and exhaustion. Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the PD-1/PD-L1 pathway have been developed for cancer immunotherapy via enhancing T cell functions. Clinical trials with mAbs to PD-1 and PD-L1 have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and bladder cancer. Further studies are needed to dissect the mechanisms of variable response rate, to identify biomarkers for clinical response, to develop small-molecule inhibitors, and to combine these treatments with other therapies.

Original languageEnglish (US)
Pages (from-to)24-33
Number of pages10
JournalTrends in Molecular Medicine
Volume21
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Immunotherapy
Ligands
Antibodies
Neoplasms
Renal Cell Carcinoma
Programmed Cell Death 1 Ligand 2 Protein
Monoclonal Antibodies
T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Death Domain Receptors
Urinary Bladder Neoplasms
Non-Small Cell Lung Carcinoma
Melanoma
Biomarkers
Clinical Trials
Therapeutics

Keywords

  • Human cancer
  • Immunotherapy
  • Monoclonal antibody
  • PD-1
  • PD-L1
  • PD-L2

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. / Ohaegbulam, Kim C.; Assal, Amer; Lazar-Molnar, Eszter; Yao, Yu; Zang, Xingxing.

In: Trends in Molecular Medicine, Vol. 21, No. 1, 2015, p. 24-33.

Research output: Contribution to journalArticle

Ohaegbulam, Kim C. ; Assal, Amer ; Lazar-Molnar, Eszter ; Yao, Yu ; Zang, Xingxing. / Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. In: Trends in Molecular Medicine. 2015 ; Vol. 21, No. 1. pp. 24-33.
@article{cb838f683b244a3c8bd627017189e214,
title = "Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway",
abstract = "The programmed death 1 (PD-1) receptor and its ligands programmed death ligand 1 (PD-L1) and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition and exhaustion. Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the PD-1/PD-L1 pathway have been developed for cancer immunotherapy via enhancing T cell functions. Clinical trials with mAbs to PD-1 and PD-L1 have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and bladder cancer. Further studies are needed to dissect the mechanisms of variable response rate, to identify biomarkers for clinical response, to develop small-molecule inhibitors, and to combine these treatments with other therapies.",
keywords = "Human cancer, Immunotherapy, Monoclonal antibody, PD-1, PD-L1, PD-L2",
author = "Ohaegbulam, {Kim C.} and Amer Assal and Eszter Lazar-Molnar and Yu Yao and Xingxing Zang",
year = "2015",
doi = "10.1016/j.molmed.2014.10.009",
language = "English (US)",
volume = "21",
pages = "24--33",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

AU - Ohaegbulam, Kim C.

AU - Assal, Amer

AU - Lazar-Molnar, Eszter

AU - Yao, Yu

AU - Zang, Xingxing

PY - 2015

Y1 - 2015

N2 - The programmed death 1 (PD-1) receptor and its ligands programmed death ligand 1 (PD-L1) and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition and exhaustion. Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the PD-1/PD-L1 pathway have been developed for cancer immunotherapy via enhancing T cell functions. Clinical trials with mAbs to PD-1 and PD-L1 have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and bladder cancer. Further studies are needed to dissect the mechanisms of variable response rate, to identify biomarkers for clinical response, to develop small-molecule inhibitors, and to combine these treatments with other therapies.

AB - The programmed death 1 (PD-1) receptor and its ligands programmed death ligand 1 (PD-L1) and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition and exhaustion. Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the PD-1/PD-L1 pathway have been developed for cancer immunotherapy via enhancing T cell functions. Clinical trials with mAbs to PD-1 and PD-L1 have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and bladder cancer. Further studies are needed to dissect the mechanisms of variable response rate, to identify biomarkers for clinical response, to develop small-molecule inhibitors, and to combine these treatments with other therapies.

KW - Human cancer

KW - Immunotherapy

KW - Monoclonal antibody

KW - PD-1

KW - PD-L1

KW - PD-L2

UR - http://www.scopus.com/inward/record.url?scp=84925529257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925529257&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2014.10.009

DO - 10.1016/j.molmed.2014.10.009

M3 - Article

C2 - 25440090

AN - SCOPUS:84925529257

VL - 21

SP - 24

EP - 33

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 1

ER -